Lita A Freeman Selected Research

Lecithin Cholesterol Acyltransferase Deficiency (Lecithin:Cholesterol Acyltransferase Deficiency)

1/2020	LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.
1/2020	Novel lecithin: cholesterol acyltransferase-based therapeutic approaches.
1/2019	Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo.
1/2019	LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency.
11/2018	Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol.
7/2018	Development of a novel fluorescent activity assay for lecithin:cholesterol acyltransferase.
1/2017	Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31.
3/2016	Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement.
1/2016	Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study.
1/2016	Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lita A Freeman Research Topics

Disease

10	Lecithin Cholesterol Acyltransferase Deficiency (Lecithin:Cholesterol Acyltransferase Deficiency) 01/2020 - 01/2016
7	Atherosclerosis 01/2020 - 11/2006
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2018
3	Hypertriglyceridemia 01/2020 - 02/2016
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 01/2022
2	Acute Coronary Syndrome 01/2020 - 07/2018
2	Coronary Disease (Coronary Heart Disease) 11/2018 - 01/2016
2	Anemia 01/2017 - 03/2016
1	Hypercholesterolemia 01/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2020
1	Cholestasis 01/2020
1	Intrahepatic Cholestasis 01/2020
1	Hyperbilirubinemia 01/2020
1	Disease Progression 01/2019
1	Obesity 01/2019
1	Proteinuria 01/2019
1	Inflammation (Inflammations) 11/2016
1	Corneal Opacity 03/2016
1	Nephrosis 01/2016
1	Autoimmune Lymphoproliferative Syndrome 01/2015
1	Dyslipidemias (Dyslipidemia) 01/2015
1	Psoriatic Arthritis 01/2015
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2015
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2015
1	Overweight 10/2012
1	Weight Loss (Weight Reduction) 10/2012

Drug/Important Bio-Agent (IBA)

10	CholesterolIBA 01/2020 - 11/2006
9	Lipoproteins (Lipoprotein)IBA 01/2020 - 11/2006
7	Phosphatidylcholine-Sterol O-Acyltransferase (Lecithin Cholesterol Acyltransferase)IBA 01/2020 - 01/2016
5	HDL CholesterolIBA 03/2016 - 10/2012
3	oxidized low density lipoproteinIBA 01/2022 - 10/2012
3	Lipoprotein-XIBA 01/2020 - 01/2016
3	LipidsIBA 01/2019 - 11/2006
3	HDL LipoproteinsIBA 01/2017 - 10/2012
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2020
2	EnzymesIBA 01/2019 - 03/2016
2	Peptides (Polypeptides)IBA 01/2018 - 02/2016
2	Apolipoprotein C-II (ApoC2)IBA 12/2017 - 02/2016
2	CytokinesIBA 11/2016 - 01/2016
2	LDL CholesterolIBA 01/2015 - 10/2012
1	LDL Receptors (LDL Receptor)IBA 01/2022
1	Proprotein Convertase 9IBA 01/2022
1	Alkaline PhosphataseIBA 01/2020
1	LecithinsIBA 01/2020
1	1-Naphthylisothiocyanate (1 Naphthylisothiocyanate)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Filipin (Filipin III)IBA 01/2019
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Cholesterol Esters (Cholesteryl Esters)IBA 01/2017
1	CyclodextrinsIBA 01/2017
1	PolymersIBA 01/2017
1	ApolipoproteinsIBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	InflammasomesIBA 11/2016
1	Apolipoproteins C (ApoC)IBA 02/2016
1	Interleukin-10 (Interleukin 10)IBA 01/2015
1	Triglycerides (Triacylglycerol)IBA 01/2015
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2015
1	SterolsIBA 01/2007
1	Apolipoproteins B (ApoB)IBA 01/2007
1	Ezetimibe (Zetia)FDA Link 01/2007

Therapy/Procedure

5	Therapeutics 01/2020 - 02/2016
3	Enzyme Replacement Therapy 01/2020 - 07/2018